Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 264-513-3 | CAS number: 63843-89-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The substance causes granulomatous inflammation in intestine, spleen and liver upon subacute oral exposure to low doses (Ciba-Geigy 1979, BASF 2012a and b). A NOAEL of 2 mg/kg bw for subacute oral dosing was identified (BASF 2012b) and the mesenteric lymph nodes were found to be the most sensitive organ.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 2 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- Valid without restriction
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Repeated dose toxicity upon oral exposure was evaluated by a weight-of-evidence approach because existing studies failed to identify a NOAEL, but showed a very distinctive pattern of toxicity involving accumulation of macrophages in the intestinal mucosa, activated macrophages in mesenteric lymph nodes, spleen and liver together with changes in organ weights and white blood cells. These parameters were further evaluated in a 28 -day dose-range finder study for testing of reproductive toxicity (BASF 2012a) and then again as additional investigations in the GLP-compliant reproductive toxicity screening study (BASF 2012b).
In summary, the test item specifically affects macrophages in exposed organs (small intestine, liver, spleen). At doses of 0.5 and 2 mg/kg bw, no adverse effects were observed . At doses of 5 mg/kg bw and higher, adverse effects were observed. Foamy macrophages couldbe seen in mesenteric lymph nodes, liver and spleen giving the clinical picture of granulomatous inflammation. This is accompanied by increases in white blood cells which is consitent with inflammation. Mortality was observed at subacute doses of 50 mg/kg bw and above. The onset of mortality shortens with increasing doses. A contribution of bacterial infection via damage of the gastrointestinal mucosa is ruled out based on the histopatholgy findings.
At 10 mg/kg bw, findings were the following: Body weight loss in 4 male animals during towards the end of the administration period, poor general condition in 2 male animals towards the end of the administration period, swelling of limbs and unsteady gait in 2 male animals towards the end of the administration period and piloerection in 1 male animal towards the end of the administration period. Haematology changes involved a d
ecreased hemoglobin and hematocrit values in both sexes, decreased red blood cell (RBC) counts in females, decreased mean corpuscular volume (MCV) and mean corpuscular hemoglobin content (MCH) in males increased platelet counts in females increased total white blood cell (WBC) counts, absolute and relative neutrophil, absolute monocyte and absolute large unstained (LUC) counts in both sexes, decreased relative lymphocyte counts in both sexes, m
inimal to moderate necrosis of the liver in 5 of 10 male animals. Histopathology findings were granulomatous inflammation with necrosis of the mesenteric lymph node in 9 of 10 male (graded marked to massive) and 9 of 10 female (graded moderate to marked) animals and granulomatous inflammation with necrosis of the spleen in 2 of 10 male (graded moderate to marked) and 2 of 10 female (graded slight to moderate) animals
Effects were observed in gavage studies (Ciba-Geigy 1979b, BASF 2012a and b) and also in a draft report of a subacute feeding study (BASF 1976) as well is in a fourteen-day non-guideline immunotoxicity study with mice (BASF 1986). The study in mice was set up as a dermal study, however no precaution was taken against preening and this was indeed reported to have occurred. Therefore, significant oral exposure has to be assumed. In this study, 70 mg/kg bw caused spleen weight increase and thymus weight decrease, but no effects on body weight or clincial signs. The substance was described to exhibit an adjuvant-type activity; details are described in the section of specific investigations. At 7 mg/kg bw, one parameter was affected and 0.7 mg/kg bw was identified as NOEL. Considering the shorter duration, the different species, and the significant oral exposure, the results and the effective dose levels are consistent with the experimental data obtained with rats and the NOAEL of 2 mg/kg bw for subacute exposure is used for the risk asssessment.
For inhalation, no information on subacute toxicity is available. Considering the physico-chemical properties, systemic availability upon inhalation needs to be assumed.
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
In this study, the NOAEL was identified. GLP compliant. All relevant parameters investigated.
Repeated dose toxicity: via oral route - systemic effects (target organ) cardiovascular / hematological: lymph nodes
Justification for classification or non-classification
Dangerous Substance Directive (67/548/EEC)
The available studies are considered in sum reliable and suitable for classification purposes under 67/548/EEC. Mortility occurred at doses of less than 150 mg/kg bw upon subacute exposure. Findings at doses of less than 15 mg/kg bw are adverse and relevant for classification and labelling (eg necroses at 10 mg/kg bw). As a result the substance is considered to be classified as toxic (T; R25) for repeated dose toxicity under Directive 67/548/EEC, as amended for the 28th time in Directive 2001/59/EC.
Classification, Labelling, and Packaging Regulation (EC) No. 1272/2008
The available experimental test data are reliable and suitable for classification purposes under Regulation 1272/2008. As a result the substance is considered to be classified in Category 1 (H372) for repeated dose toxicity under Regulation (EC) No. 1272/2008, as amended for the second time in Directive (EC 286/2011). The lymph nodes were identified as the most sensitive target organ for repeated exposure.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.